Immunome (IMNM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of three Class III directors to serve until the 2029 Annual Meeting or until successors are qualified.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Advisory vote on the preferred frequency of future say-on-pay votes, with 'Year' as the recommended frequency.
Board recommends voting 'For' all proposals and nominees.
Board of directors and corporate governance
Three nominees for Class III director positions: James Boylan, Sandra M. Swain, M.D., and Philip Wagenheim.
Directors to serve until 2029 or until successors are elected and qualified.
Executive compensation and say-on-pay
Advisory vote to approve compensation of named executive officers.
Advisory vote to determine frequency of future say-on-pay votes, with annual voting recommended.
Latest events from Immunome
- FDA accepted NDA for varegacestat; Q2 net loss $73.1M, cash $520M, pipeline advancing.IMNM
Q2 2026 - Advancing global ADC and targeted therapy pipeline, with pivotal AL102 data expected in 2025.IMNM
Guggenheim Securities Inaugural Healthcare Innovation Conference - Varegacestat nears pivotal data with strong differentiation, while ADC innovation advances.IMNM
Guggenheim Securities 2nd Annual Healthcare Innovation Conference - All proposals passed, including director elections and auditor ratification, with no shareholder questions.IMNM
AGM 2026 - Varegacestat shows strong efficacy as launch nears; ADC pipeline and cash runway support growth.IMNM
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Varegacestat met all Phase 3 endpoints in desmoid tumors, with NDA filed and strong pipeline progress.IMNM
Investor presentation - NDA filed for varegacestat after strong Phase 3; Q1 net loss $53.8M, cash $582.7M.IMNM
Q1 2026 - 2025 achievements drove pipeline and share growth; Board recommends all proposals at 2026 meeting.IMNM
Proxy filing - Varegacestat achieved best-in-class efficacy and safety in Phase 3 desmoid tumor trial.IMNM
Study Result